The Latest Breaking News on Pharma

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

In a New York Times essay, Andrew Witty also says slain healthcare CEO Brian Thompson cared about customers

Consultancy giant agrees to two criminal counts, including for conspiring with drug manufacturers, in DoJ settlement

McKinsey & Company agrees to pay 0 million in settlement for its role in Purdue Pharma's opioid crisis, impacting addiction and overdose prevention efforts.

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

The competition watchdog was investigating whether the drugs firm had been spreading misleading information on a rival’s treatment.